Medical Training AIKetamine and Esketamine for Depression
You'll be able to evaluate a patient for treatment-resistant depression, select an appropriate ketamine or esketamine pathway, and monitor safely through and after administration.
What this track covers
This track covers IV ketamine and intranasal esketamine for treatment-resistant depression, from mechanism and patient selection through administration safety and post-treatment monitoring. It also addresses REMS requirements for esketamine and how a monitoring workflow fits into ongoing patient care.
What you will practice
- Screen a patient for treatment-resistant depression and identify contraindications
- Differentiate when IV ketamine versus intranasal esketamine may be considered
- Set up a monitoring plan for dissociative effects and vital signs during administration
- Recognize and respond to adverse events during or after a session
- Apply esketamine REMS monitoring requirements to a clinic workflow
Simulator scenario
A patient with treatment-resistant depression presents for an initial esketamine session and develops dissociative symptoms and a blood pressure change during the monitored observation period.
Board question topics
- Patient selection criteria for treatment-resistant depression
- REMS requirements for esketamine administration
- Monitoring parameters during ketamine/esketamine sessions
- Recognizing and managing adverse events post-administration
Ask the tutor
The tutor only answers from licensed sources (FDA prescribing information, public guidelines and our own material) and says when it has none. Educational use only, never patient-specific advice.
Free during the beta. Sign in with your email, no password.
Start free